What’s going on with IMV?
Shares of IMV, Inc. (IMV) surged today after the company announced the first final results of its Phase 2 DeCidE1 clinical trial evaluating maveropepimut-S (MVP-S) in subjects with advanced recurrent ovarian cancer. IMV called the results “very promising” and said “the treatment was well tolerated with an overall survival rate of 44.9% at 23.8 months of follow-up.”
IMV’s lead candidate, maveropepimut-S (formerly called DPX-Survivac), is a T cell activating immunotherapy that combines the utility of its proprietary delivery platform (DPX) with survival, a new cancer target.
Shares of IMV rose 24.34% to $ 2.089 at 10:46 a.m. on Tuesday.
What does this mean for IMV, Inc?
“DeCidE1” was a multicenter, randomized, open-label phase 1b / 2 study to evaluate the safety and efficacy of MVP-S with intermittent low doses of cyclophosphamide. The trial recruited 22 subjects and was significant because the patients had advanced platinum-sensitive and resistant ovarian cancer.
Dr Jeremy Graff, Scientific Director of IMV commented, “Translational assays provide strong evidence that maveropepimut-S successfully induces the generation of tumor antigen-specific T cells. Importantly, these analyzes confirm the molecular and cellular mechanism of therapy based on MVP-S. “
These data will inform the discussion and design of a Phase 2 clinical study that will be submitted to the FDA.
IMV has a fundamental ranking of 98. Find out what this means to you and get the rest of the ranking on IMV!
IMV Inc is a clinical stage biopharmaceutical company. The company is committed to making immunotherapies more effective, more widely applicable, and more widely accessible to people facing cancer and other serious illnesses. Its proprietary drug development platform provides a patented delivery formulation that allows controlled and prolonged exposure of antigens to the immune system.